文献速递治疗药物监测与药物基因组学抗栓抗凝管理药物不良反应与药物警戒

中国急性冠脉综合征患者替格瑞洛血药浓度与出血事件的关联

Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome.
PubMed 文献 · Br J Clin Pharmacol · 2022-06-19

该研究纳入631例接受阿司匹林联合替格瑞洛双联抗血小板治疗的急性冠脉综合征患者,随访12个月,检测替格瑞洛及其主要活性代谢物的谷浓度并分析10个单核苷酸多态性。结果发现出血事件患者替格瑞洛浓度显著高于无出血事件者,预测出血的浓度截断值为363.3 ng/mL,P2Y12基因多态性与浓度及出血相关。

要点

  • 中国ACS患者替格瑞洛谷浓度与出血事件独立相关。
  • 出血事件患者替格瑞洛中位浓度322.6 ng/mL,显著高于无出血者的222.1 ng/mL。
  • 预测出血的替格瑞洛浓度截断值为363.3 ng/mL(AUC=0.65)。

核心结论

  • 中国急性冠脉综合征患者替格瑞洛血浆浓度与出血事件存在关联。

研究设计与样本

  • 纳入631例确诊急性冠脉综合征并接受阿司匹林联合替格瑞洛双联抗血小板治疗的患者,随访12个月。
  • 检测替格瑞洛及其主要活性代谢物的谷浓度,并鉴定10个与替格瑞洛药代动力学和安全性相关的单核苷酸多态性。

主要发现

  • 133例患者发生出血学术研究联合会(BARC)1型或2型出血事件。
  • 出血事件患者替格瑞洛中位浓度(四分位距)为322.6 ng/mL(196.2-458.0 ng/mL),显著高于无出血事件患者的222.1 ng/mL(140.4-341.9 ng/mL),P < .001。
  • 受试者工作特征曲线显示,预测出血事件的替格瑞洛浓度截断值为363.3 ng/mL(曲线下面积=0.65;P < .001,95% CI:0.595-0.700)。
  • 药物基因组学结果显示,P2Y12(rs6787801,P = .024)和P2Y12(rs6785930,P = .048)分别与替格瑞洛浓度和出血事件有统计学关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The risk of ticagrelor-related bleeding events remains a major clinical concern, especially in East Asian populations. Previous studies have reported higher ticagrelor exposure in Asian patients than in Caucasians. This prompted us to investigate the correlation between ticagrelor concentrations and bleeding events. METHODS: Patients diagnosed with acute coronary syndrome and receiving dual antiplatelet therapy (aspirin and ticagrelor) were enrolled and followed up for 12 months. Trough plasma concentrations of ticagrelor and a major active metabolite were assayed, and 10 single nucleotide polymorphisms associated with ticagrelor pharmacokinetics and safety were also identified. RESULTS: A total of 631 patients were included and 133 patients had bleeding academic research consortium type 1 or 2 bleeding event. The median ticagrelor concentration (interquartile range) was significantly higher in patients with bleeding events than that in patients without bleeding events (322.6 ng/mL [196.2-458.0 ng/mL] vs. 222.1 ng/mL [140.4-341.9 ng/mL], P < .001). According to the receiver operating characteristic curve, the cut-off value for ticagrelor levels predicting bleeding events was 363.3 ng/mL (area under the curve = 0.65; P < .001, 95% Cl: 0.595-0.700). Pharmacogenomics results showed that P2Y12 (rs6787801, P = .024) and P2Y12 (rs6785930, P = .048) were statistically associated with ticagrelor levels and bleeding events, respectively. CONCLUSION: Ticagrelor plasma concentrations were associated with bleeding events in Chinese patients with acute coronary syndrome.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yang J, Qi G, Hu F, et al. Association between ticagrelor plasma concentration and bleeding events in Chinese patients with acute coronary syndrome. Br J Clin Pharmacol. 2022. PMID: 35644848. doi:10.1111/bcp.15422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。